Amazentis, an innovative company in the field of fighting aging as a pathology and not just a human condition, announced a publication in the journal Nature Metabolism in collaboration with researchers from the École Polytechnique Fédérale de Lausanne (EPFL) and the Swiss Institute of Bioinformatics (SIB) showing the safety and effectiveness of Urolithin A in improving the health of cells and mitochondria.
After the first, extraordinary results of animal tests in 2016 (survival in some species increased up to 45%), Urolithin A was administered orally in a single and double daily dose for 4 weeks to 60 healthy elderly subjects in scope of a double-blind experiment.
Roger Fielding, Professor of Medicine and Nutrition and Associate Director of the Jean Mayer Research Center at Tuft University commented: “Currently there were no effective solutions other than regular exercise to combat the decline in muscle function. This is a first, important clinical validation showing the promising role of Urolithin A in management of health muscular as the years advance”.
“Cellular and mitochondrial health declines with age: the discovery of one substance capable of stopping, managing or reversing this decline is a milestone in medicine,” says Patrick Aebischer, co-author of the article.
“These positive results for Urolithin A show its potential in improving the cellular health through mitophagy and biogenesis,” adds Johan Auwerx, the other co-author.
Here is the original article: https://www.businesswire.com/news/home/20190614005279/en/
